Tarceva

Type: Product
Name: Tarceva
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Roche Sees Second Phase III Setback of 2014 as MetMab Flops

Roche today acknowledged its second failed pivotal clinical trial this year by halting its Phase III METLung study of its MetMab (onartuzumab) in combination with Astellas Pharma’s Tarceva (erlotinib) for previously treated, advanced non-small cell lung ... [Published Genetic Engineering News - Aug 29 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer

Background. EGFR and Src are frequently activated in non-small cell lung cancer (NSCLC). In preclinical models, combining EGFR and Src inhibition has additive synergistic effects. We conducted a phase I/II trial of the combination of Src inhibitor dasatinib ... [Published The Oncologist - Aug 29 2014]
First reported Aug 27 2014 - Updated Aug 28 2014 - 5 reports

‘Miriam for president’ Senator says she can ‘rise to the occasion’

BY PRINCE GOLEZManila ReporterMANILA – Iloilo City’s Sen. Miriam Defensor-Santiago, battling stage 4 lung cancer, may run for president in 2016.“I am not going to be coy. Society leaders have urged me to seek the presidency,” said Santiago.The feisty ... [Published Panay News - Aug 27 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Investigators at National Taiwan University Discuss Findings in Cancer Gene Therapy (CIP2A mediates erlotinib-induced apoptosis in non-small cell...

Investigators at National Taiwan University Discuss Findings in Cancer Gene Therapy (CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation)By a News Reporter-Staff News Editor at Cancer Gene Therapy Week ... [Published HispanicBusiness.com - Aug 28 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Forum Post: RE: Tarceva

Hi Carol.I have been on Tarceva for just over a year. For me it has been very easy to tolerate.I have carried on working and the side effects have been mostly short lived and manageable. First side effects usually appear in a few days and normally a rash ... [Published Macmillan Cancer Support - Aug 26 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Erlotinib feasible in KRAS wild-type lung adenocarcinoma

Erlotinib is a valid treatment option for patients with KRAS wild-type lung adenocarcinoma refractory to chemotherapy, study data show.To determine the clinical significance of KRAS mutational status in response to erlotinib, Balazs Dome (Medical University ... [Published News-Medical.Net - Aug 21 2014]
First reported Aug 19 2014 - Updated Aug 20 2014 - 2 reports

NIH launches 3 integrated precision medicine trials

The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, or ALCHEMIST, was launched to identify early-stage lung cancer patients with tumours that harbor certain uncommon genetic changes and evaluate whether drug treatments targeted ... [Published PharmaBiz - Aug 20 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy

ReferencesHuebner G, Link H, Kohne CH, et al: Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer 2009;100:44-49.Hainsworth ... [Published Sexual Development - Aug 19 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Mixed Results for Targeting MET in Non–Small Cell Lung Cancer

D. Ross Camidge, MDTargeting MET in Lung CancerOur results suggest that MET-amplified disease may represent a novel targetable subtype of NSCLC, notably present among those with smoking activity.—D. Ross Camidge, MDTwo different abstracts explored the ... [Published The ASCO Post - Aug 15 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 2 reports

NICE Tarceva Restrictions ‘Leave NSCLC Patients Without Options,’ Roche Says

Related Biotechnology, Pharmaceutical and Healthcare NewsNICE has cleared Roche’s Tarceva as second-line therapy but restricted its indication so severely that it barely puts it ahead of a competing pack of NSCLC therapies – and effectively cuts options ... [Published BioPortfolio - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

Non-small cell lung cancer consultation

The National Institute for Health and Care Excellence (NICE) is consulting  on its review of the use of erlotinib (Tarceva; Roche) and gefitinib (Iressa; AstraZeneca) for the treatment of non-small cell lung cancer that has progressed after prior chemotherapy. The ... [Published Pharmaceutical Journal - Aug 11 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 3 reports

NICE comes back with different views on Tarceva and Iressa for NSCLC

UK health costs watch dog the National Institute for Health and Care Excellence (NICE) is consulting again on its review of existing guidance on the use of Swiss drug major Roche’s (ROG: SIX) Tarceva (erlotinib) and Anglo-Swedish pharma firm AstraZeneca’s ... [Published Pharma Letter - Aug 07 2014]

Quotes

"These results are disappointing because new options are needed for patients with lung cancer, the most common and deadly cancer worldwide,” Sandra Horning, M D , CMO and head of global product development. "We remain committed to helping patients with lung cancer and are studying several investigational medicines in this disease.”"
"In this case, the abovementioned resistance mutation is preferably T3151. Moreover, the abovementioned activation mutation is preferably bcr-abl."

More Content

All (169) | News (139) | Reports (0) | Blogs (27) | Audio/Video (0) | Fact Sheets (2) | Press Releases (0)
sort by: Date | Relevance
Roche Sees Second Phase III Setback of 2014 as ... [Published Genetic Engineering News - Aug 29 2014]
A Phase I/II Study Combining Erlotinib and Dasa... [Published The Oncologist - Aug 29 2014]
Mutant allele frequency predicts lung cancer TK... [Published News-Medical.Net - Aug 28 2014]
Researchers Submit Patent Application, "Method ... [Published 4 Traders - Aug 28 2014]
AJINOMOTO : Patent Application Titled "Therapeu... [Published 4 Traders - Aug 28 2014]
Investigators at National Taiwan University Dis... [Published HispanicBusiness.com - Aug 28 2014]
Efficacy of Second-Line Oxaliplatin, Leucovorin... [Published Chemotherapy Advisor - Aug 27 2014]
‘Miriam for president’ Senator says she can ‘ri... [Published Panay News - Aug 27 2014]
Miriam hints at running for president in 2016 p... [Published Philippines Daily Tribune - Aug 27 2014]
Recovering from cancer, Miriam eyes presidency ... [Published Philippine Star - Aug 27 2014]
Miriam says she has beaten cancer, may run for ... [Published Interaksyon - Aug 27 2014]
‘Recovering’ Miriam might run for president [Published Rappler - Aug 27 2014]
Diagnostics are rising up the pharma value chain [Published PMLive - Aug 27 2014]
Forum Post: RE: Tarceva [Published Macmillan Cancer Support - Aug 26 2014]
Forum Post: RE: Thanks for Tarceva! One year to... [Published Macmillan Cancer Support - Aug 22 2014]
Forum Post: Thanks for Tarceva! One year today!! [Published Macmillan Cancer Support - Aug 22 2014]
Erlotinib feasible in KRAS wild-type lung adeno... [Published News-Medical.Net - Aug 21 2014]
Celgene's cost-sharing offer persuades NICE to ... [Published FiercePharma - Aug 20 2014]
NIH launches 3 integrated precision medicine tr... [Published PharmaBiz - Aug 20 2014]
NIH launches trial of genetically targeted lung... [Published MedCity News - Aug 19 2014]
Carcinoma of Unknown Primary Site Treated with ... [Published Sexual Development - Aug 19 2014]
Dana-Farber to Lead Early-Stage Lung Cancer Trial [Published Boston Magazine - Aug 19 2014]
The Negative Impact Of Pfizer's Mergers And Bud... [Published Forbes.com - Aug 19 2014]
Non Small Cell Lung Cancer Market worth $7.9 bi... [Published EMAILWIRE.com - Aug 19 2014]
Lung Cancer Alliance Applauds Launch of Innovat... [Published Myrtle Beach Sun News - Aug 18 2014]
Variable NF-kappaB pathway responses in colon c... [Published BMC - Aug 18 2014]
Non-Small Cell Lung Cancer Market to 2020 Trend... [Published MyNewsDesk - Aug 18 2014]
Roche set to buy Chugai in $10bn deal [Published Nigeria Punch - Aug 18 2014]
Lung cancer drug in clinical trial at hospital [Published Darrien News-Review - Aug 16 2014]
Roche To Buy Chugai For $10 Billion [Published Bidness Etc - Aug 16 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Advancing medicine, layer by layer [Published MIT News feed - Jul 01 2014]
Personalized cancer treatments and better bone implants could grow from techniques demonstrated by graduate students Stephen W. Morton and Nisarg J. Shah, who are both working in chemical engineering professor Paula Hammond's lab at MIT. Morton's work ...
Tarceva Forecast [Published PR Newswire: Entertainment & Media - Jun 19 2014]
NEW YORK, June 19, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Tarceva Forecasthttp://www.reportlinker.com/p02162048/Tarceva-Forecast.htmlThe BCC Research Tarceva Forecast is a quantitative ...
Faculty highlight: Paula Hammond [Published MIT News feed - Jun 18 2014]
As a chemical engineer, Paula Hammond began her career getting tiny polymers to transform when heated or stretched — by changing color, for example. But her passion turned to using those techniques to promote healing. That led her to engineer better ...
FibroGen Announces Results of Phase 2 Study of ... [Published Business Wire Health News - May 31 2014]
CHICAGO--(BUSINESS WIRE)--FibroGen, Inc. (FibroGen) today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally ...
Genprex Begins Phase II Clinical Trial for Lung... [Published PR Newswire: Health - May 20 2014]
AUSTIN, Texas, May 20, 2014 /PRNewswire/ -- Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. ...
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.